Use of aluminum-based phosphate-chelators in hemodialysis in the era of ultrapure water;Uso de captores alumínicos en hemodiálisis en la era del agua ultrapura

Nefrologia

Volumn 28, Issue 2, 2008, Pages 168-173

  Arenas Jiménez, Ma Dolores ^a   Malek, T ^b   Gil, M T ^b   Moledous, A ^b   Nunez C ^b   Alvarez Ude F ^b  

^a HOSPITAL PERPETUO SOCORRO   (Spain)

^b NONE

Author keywords

Aluminium phosphate binder; Haemodialysis; Osmosis inverse; Phosphorus

Indexed keywords

ALUMINUM HYDROXIDE; CHELATING AGENT; PHOSPHATE;

AGED; ARTICLE; FEMALE; HUMAN; HYPERPHOSPHATEMIA; MALE; METABOLISM; RENAL REPLACEMENT THERAPY;

AGED; ALUMINUM HYDROXIDE; CHELATING AGENTS; FEMALE; HUMANS; HYPERPHOSPHATEMIA; MALE; PHOSPHATES; RENAL DIALYSIS;

EID: 51149099992     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Arenas MD, Álvarez-Ude F, Gil MT, Soriano A, Egea JJ, Millán I, Amoedo ML, Muray S, Carretón MA. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 2006; 21 (6): 1663-8.
2. Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B; Alberta Kidney Disease Network. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22 (10): 2856-66.
3. Salusky IB. A new era in phosphate binder therapy: what are the options? Kidney Int Suppl 2006; (105): S10-5.
4. Clinical practice Guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (4) Supl. 3: 1-201.
5. Dialysis dementia in Europe. Report from registration committee of the European Dialysis Transplant Association. Lancet 1980; 2 (8187): 190-2.
6. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminium intoxication. N Engl J Med 1976; 294 (4): 184-8.
7. Altmann P, Dhanesha U, Hamon C, Cunningham J, Blair J, Marsh F. Disturbance of cerebral function by aluminium in haemodialysis patients without overt aluminium toxicity. Lancet 1989; 2 (8653): 7-12.
8. Swartz R, Dombrouski J, Burnatowska-Hledin M, Mayor G. Microcytic anemia in diálisis patients:reversible marker of aluminum toxicity. Am J Kidney Dis 1987; 9 (3): 217-23.
9. McGonigle RJS, Parsons V. Aluminium -induced anaemia in hemodialysis patients. Nephron 1985; 39: 1-9.
10. Ward MK, Feest TG, Ellis HA, Parkinson IS, Kerr DN. Osteomalacic dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminium. Lancet 1978; 1: 841-845.
11. Parkinson IS, Ward MK, Feest TG, Fawcett RW, Kerr DN. Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey. Lancet 1979; 1: 406-409.
12. AAMI Standards and recommended practices, Arlington, Virginia, published by the Association for the Advancement of medical instrumentation, 3: Dialysis, 1993.
13. European Pharmacopoeia, 1997: Haemodialysis solutions, concentrated, water for diluting.
14. Pérez García R, González Parra E, Ceballos F, Escallada Cotero R, Gómez-Reino MI, Martín-Rabadán P, Pérez García A, Ramírez Chamond R, Sobrino PE, Solozábal C; Spanish Society of Nephrology. Guías de gestión de calidad del líquido de diálisis. Nefrología 2004; 24 Supl. 2: 1-42.
15. Fernández Martín JL, Cannata JB. Evolution of the aluminum concentration in the final dialysis solution: multicenter study in Spanish dialysis centers. Nefrología 2000; 20 (4): 342-7.
16. Simoes J, Barata JD, D'Haese PC, De Broe ME: Cela n'arrive qu'aux autres (alumininium intoxication only happens in the other nephrologist's dialysis center). Nephrol Dial Transplant 1994; 9: 67-68.
17. D'Haese PC; Clement JP, Elseviers MM y cols. Value of serum aluminium monitoring in dialysis patients: a multicentre study. Nephrol Dial Transplant 1990; 5: 45-53.
18. Smith AJ, Faugére M-C, Abreo K, Fanti P, Julián B, Malluche HH. Aluminum -related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol 1986; 6: 275-283.
19. Andress DL, Maloney NB, Endres DB, Sherrard DJ. Aluminum-associated bone disease in chronic renal failures: high prevalence in a long-term dialysis population. Journal of bone and mineral research 1986; 1: 391-398.
20. Charhon SA, Chavassieux PM, Meunier PJ, Accominotti M. Serum aluminium concentration and aluminium deposits in bone in patients receiving haemodialysis. British Medical J 1985; 290: 1613-1614.
21. Consensus Conference. Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Nephrol Dial Transplant 1993; Supl. 1: 1-4.
22. Coburn JW, Mischel MG, Goodman WG, Salusky IB. Calcium citrate markedly enhances aluminium absorption from aluminium hydroxide. Am J Kidney Dis 1991; 17: 708-711.
23. Cannata JB. Aluminium toxicity: its relationship with bone and iron metabolism. Nephrol Dial Transplant 1996; 11 (Supl. 3): 69-73.
24. Douthat W, Acuña G, Fernández Martín JL, Serrano M, González Caicedo A, Canteros A, Menéndez Fraga P, Cannata JB. Exposición al aluminio y calidad del baño de diálisis: repercusión sobre los niveles de aluminio sérico. Nefrología 1994; 14 (6): 695-700.
25. Mazzaferro S, Perruzza I, Costantini S, Pasquali M, Onorato L, Sardella D, Giordano R, Ciaralli L, Ballanti P, Bonucci E, Cinotti GA, Coen G. Relative roles of intestinal absorption and dialysis-fluid-related exposure in the accumulation of aluminium in haemodialysis patients. Nephrol Dial Transplant 1997; 12 (12): 2679-82.
26. Fernández Martín JL, Cannata JB. Evolución de la concentración de aluminio en la solución final de diálisis: estudio multicéntrico en centros de diálisis españoles. Nefrología 2000; 20 (4): 342-347.
27. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15 (8): 2208-18.
28. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with the end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
29. White CA, Jaffey J, Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int 2007; 71 (4): 312-7.
30. Kimata N, Akiba T, Pisoni RL, Albert JM, Satayathum S, Cruz JM, Akizawa T, Andreucci VE, Young EW, Port FK. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2005; 20 (5): 927-35.
31. Arenas MD, Álvarez-Ude F, Gil MT, Moledous A, Malek T, Núñez C, Devesa R, Carretón MA, Soriano A. Implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007; 22 (6): 1639-44.
32. De Freitas D, Donne RL, Hutchison AJ. Lanthanum carbonate -a first line phosphate binder? Semin Dial 2007; 20 (4): 325-8.